• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项建立高分子量尿型纤溶酶原激活剂(HMW/u-PA)标准的合作研究。

A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA).

作者信息

Gaffney P J, Heath A B

机构信息

Division of Haematology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.

出版信息

Thromb Haemost. 1990 Nov 30;64(3):398-401.

PMID:2128969
Abstract

An international collaborative study involving eleven laboratories located in eight countries was undertaken to establish an International Standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA). The current International Reference Preparation (IRP code numbered 66/46) for urinary-type plasminogen activator (u-PA) or urokinase (see Nomenclature footnote) is a 66/34 molar ratio mixture of low molecular weight (LMW)--and high molecular weight (HMW)--u-PA's and is considered unsuitable as a standard for homogeneous preparations of HMW/u-PA. The putative standard for HMW/u-PA (code number, 87/594) was compared for potency in a clot lysis assay with the current IRP for u-PA (code number, 66/46) and a lyophilised preparation of single chain urinary-type plasminogen activator (SCuPA), the latter being used in the assay without prior activation by plasmin to its active two chain form (TCuPA). Both the proposed standard for HMW/u-PA (87/594) and the SCuPA compared in a statistically satisfactory manner in parallel line bioassays with the current IRP for u-PA (66/46), thus allowing potency estimates to be obtained for these two materials in relation to defined international units. Data from the eleven laboratories indicated that each ampoule of the proposed standard for HMW/u-PA contained 4,300 i.u. of activity and was stable for over 1 year at 4 degrees C. Most participants indicated that SCuPA expressed only a small amount of its activity without a prior activator step and this suggests that SCuPA assays need to be preceded by a plasmin activation step.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

一项涉及八个国家11个实验室的国际合作研究旨在建立高分子量尿型纤溶酶原激活剂(HMW/u-PA)的国际标准。目前尿型纤溶酶原激活剂(u-PA)或尿激酶(见命名注释)的国际参考制剂(IRP编号66/46)是低分子量(LMW)和高分子量(HMW)u-PA的66/34摩尔比混合物,被认为不适用于HMW/u-PA均匀制剂的标准。将HMW/u-PA的假定标准品(编号87/594)在凝块溶解试验中的效力与当前u-PA的IRP(编号66/46)以及单链尿型纤溶酶原激活剂(SCuPA)的冻干制剂进行比较,后者在试验中未经纤溶酶预先激活成其活性双链形式(TCuPA)就被使用。HMW/u-PA的提议标准品(87/594)和SCuPA在与当前u-PA的IRP(66/46)的平行线生物测定中在统计学上比较令人满意,从而可以获得这两种物质相对于规定国际单位的效力估计值。来自11个实验室的数据表明,HMW/u-PA提议标准品的每个安瓿含有4300国际单位的活性,并且在4℃下可稳定保存1年以上。大多数参与者表示,SCuPA在没有预先激活步骤的情况下仅表现出少量活性,这表明SCuPA测定需要在纤溶酶激活步骤之前进行。(摘要截短为250字)

相似文献

1
A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA).一项建立高分子量尿型纤溶酶原激活剂(HMW/u-PA)标准的合作研究。
Thromb Haemost. 1990 Nov 30;64(3):398-401.
2
A collaborative study to establish the 2nd international standard for tissue plasminogen activator (t-PA).一项建立组织型纤溶酶原激活剂(t-PA)第二个国际标准的合作研究。
Thromb Haemost. 1987 Dec 18;58(4):1085-7.
3
Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator.低分子量和高分子量单链尿激酶型纤溶酶原激活剂的体外纤溶活性比较
Thromb Haemost. 1993 Sep 1;70(3):481-5.
4
A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA).一项关于组织型纤溶酶原激活剂(t-PA)拟议国际标准的合作研究。
Thromb Haemost. 1985 Feb 18;53(1):134-6.
5
The international standard for plasminogen activator inhibitor-1 (PAI-1) activity.纤溶酶原激活物抑制剂-1(PAI-1)活性的国际标准。
Thromb Haemost. 1996 Jul;76(1):80-3.
6
A comparison of the plasminogen activator activity units of urinary-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA).尿型纤溶酶原激活剂(u-PA)与组织型纤溶酶原激活剂(t-PA)的纤溶酶原激活剂活性单位比较。
Blood Coagul Fibrinolysis. 1992 Aug;3(4):481-3.
7
Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.由组织型纤溶酶原激活剂的NH2末端区域和尿激酶型纤溶酶原激活剂的COOH末端区域组成的嵌合纤溶酶原激活剂在纯化系统和人血浆中的抑制作用。
Thromb Haemost. 1988 Oct 31;60(2):247-50.
8
An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein.对正常血浆以及缺乏因子XII和前激肽释放酶的血浆中硫酸葡聚糖优球蛋白组分中单链尿激酶型纤溶酶原激活剂(scu-PA)激活剂的分析。
Thromb Haemost. 1991 Feb 12;65(2):144-8.
9
Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators.深入了解硫酸皮肤素的纤溶活性:对组织型和尿激酶型纤溶酶原激活物介导的纤溶酶原激活的影响。
Thromb Res. 2007;120(5):745-52. doi: 10.1016/j.thromres.2006.12.014. Epub 2007 Jan 31.
10
Influence of low- and high-molecular-weight plasminogen activators on the onset of labor and on the hemostatic system.低分子量和高分子量纤溶酶原激活剂对分娩发动及止血系统的影响。
Semin Thromb Hemost. 2002 Dec;28(6):529-32. doi: 10.1055/s-2002-36696.